TPCW
UTHR icon

TD Private Client Wealth’s United Therapeutics UTHR Stock Holding History

TD Private Client Wealth’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$716K Sell
1,321
-1,440
-52% -$811K 0.01% 434
2026
Q1 		$1.64M Sell
2,761
-675
-20% -$336K 0.03% 278
2025
Q4 		$1.67M Sell
3,436
-945
-22% -$440K 0.04% 273
2025
Q3 		$1.84M Sell
4,381
-291
-6% -$97.9K 0.04% 255
2025
Q2 		$1.34M Sell
4,672
-90
-2% -$26.9K 0.03% 303
2025
Q1 		$1.47M Buy
4,762
+1,092
+30% +$374K 0.04% 279
2024
Q4 		$1.29M Sell
3,670
-18
-0.5% -$6.62K 0.04% 306
2024
Q3 		$1.32M Buy
3,688
+358
+11% +$121K 0.04% 322
2024
Q2 		$1.06M Buy
3,330
+26
+0.8% +$6.88K 0.03% 336
2024
Q1 		$759K Buy
3,304
+135
+4% +$30.5K 0.02% 387
2023
Q4 		$697K Sell
3,169
-139
-4% -$32K 0.03% 387
2023
Q3 		$747K Sell
3,308
-834
-20% -$192K 0.03% 354
2023
Q2 		$914K Sell
4,142
-248
-6% -$54.9K 0.04% 352
2023
Q1 		$983K Sell
4,390
-281
-6% -$69.3K 0.04% 330
2022
Q4 		$1.3M Sell
4,671
-1,197
-20% -$302K 0.06% 280
2022
Q3 		$1.23M Sell
5,868
-182
-3% -$40.7K 0.06% 272
2022
Q2 		$1.43M Sell
6,050
-777
-11% -$158K 0.07% 260
2022
Q1 		$1.22M Buy
6,827
+998
+17% +$190K 0.05% 311
2021
Q4 		$1.26M Sell
5,829
-2,448
-30% -$481K 0.05% 308
2021
Q3 		$1.53M Buy
+8,277
New +$1.63M 0.07% 276
2020
Q4 		– Sell
-15
Closed -$1.51K – 1167
2020
Q3 		$1.51K Hold
15
– – ﹤0.01% 937
2020
Q2 		$1.81K Hold
15
– – ﹤0.01% 921
2020
Q1 		$1.42K Hold
15
– – ﹤0.01% 909
2019
Q4 		$1.32K Buy
+15
New +$1.32K ﹤0.01% 937

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

TD Private Client Wealth's UTHR Position: Q2 2026 in Review

TD Private Client Wealth reduced its United Therapeutics (UTHR) stake by 52% in Q2 2026, selling an estimated $811K and leaving 1,321 shares worth $716K. The position accounts for 0.01% of the portfolio, ranked #434.

TD Private Client Wealth first reported a position in UTHR in Q4 2019 and has held it in 24 quarters since. The position peaked at $1.84M in Q3 2025. 879 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • TD Private Client Wealth held 1,321 shares of United Therapeutics worth $716K as of Q2 2026.
  • TD Private Client Wealth sold 1,440 United Therapeutics shares in Q2 2026, an estimated $811K.
  • United Therapeutics made up 0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #434 holding.
  • TD Private Client Wealth first reported a position in United Therapeutics in Q4 2019 and has held it in 24 quarters since.
  • TD Private Client Wealth's United Therapeutics position peaked at $1.84M in Q3 2025.
  • 879 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.